76 related articles for article (PubMed ID: 8333190)
21. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
22. Expression of programmed cell death proteins in patients with chronic myeloid leukemia.
Strnad M; Brajuskovic G; Strelic N; Todoric-Zivanovic B; Stamatovic D; Tatomirovic Z; Magic Z
J BUON; 2008; 13(3):403-8. PubMed ID: 18979557
[TBL] [Abstract][Full Text] [Related]
23. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
[TBL] [Abstract][Full Text] [Related]
24. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
25. [Reversion to chronic phase of chronic myelogenous leukemia in blast crisis with small-dose daunorubicin and oral prednisolone].
Kuyama J; Take H
Rinsho Ketsueki; 1995 Dec; 36(12):1353-8. PubMed ID: 8587171
[TBL] [Abstract][Full Text] [Related]
26. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders.
Peeters P; Wlodarska I; Baens M; Criel A; Selleslag D; Hagemeijer A; Van den Berghe H; Marynen P
Cancer Res; 1997 Feb; 57(4):564-9. PubMed ID: 9044825
[TBL] [Abstract][Full Text] [Related]
27. Cytogenetic and molecular mechanisms of resistance to imatinib.
Hochhaus A
Semin Hematol; 2003 Apr; 40(2 Suppl 2):69-79. PubMed ID: 12783379
[TBL] [Abstract][Full Text] [Related]
28. Myeloperoxidase cytochemical negativity: an unexpected but intrinsic property of blasts of all phases of chronic myeloid leukemia.
Anand M; Ghara N; Kumar R; Singh S; Sengar M; Panikar N; Raina V; Sharma A
Ann Hematol; 2005 Nov; 84(12):767-70. PubMed ID: 15990995
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic transplantation of CD34+-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation.
Urbano-Ispizua A; Brunet S; Solano C; Moraleda JM; Rovira M; Zuazu J; de La Rubia J; Bargay J; Caballero D; Díez-Martín JL; Ojeda E; Pérez de Oteiza JP; Ferrá C; Espigado I; Alegre A; de La Serna J; Torres P; Riu C; Odriozola J; Rozman C; Sierra J; García-Conde J; Montserrat E;
Bone Marrow Transplant; 2001 Aug; 28(4):349-54. PubMed ID: 11571506
[TBL] [Abstract][Full Text] [Related]
30. High expression of RbAp46 gene in patients with acute leukemia or chronic myelogenous leukemia in blast crisis.
Hu SY; Chen ZX; Gu WY; Cen JN; Zhao Y
Chin Med J (Engl); 2005 Aug; 118(15):1295-8. PubMed ID: 16117885
[No Abstract] [Full Text] [Related]
31. [The functional activity of blood neutrophils in chronic myeloleukemia].
Asadov ChD; Numerova LS
Lab Delo; 1990; (10):59-61. PubMed ID: 1704464
[No Abstract] [Full Text] [Related]
32. [The comparative characteristics of the clinico-hematological indices in patients with different forms of myelodysplasias].
Pesotskaia LA
Lik Sprava; 1997; (2):59-62. PubMed ID: 9333486
[TBL] [Abstract][Full Text] [Related]
33. [Factors affecting the DNA-binding activity of the blood serum in in patients and healthy persons at low ionic strength].
Podgorodnichenko VK; Tsypliakovskaia LM; Saenko AS; Bryksina LE; Poverennyĭ AM
Vopr Med Khim; 1979; 25(3):278-82. PubMed ID: 452492
[TBL] [Abstract][Full Text] [Related]
34. [Molecular heterogeneity and complex-forming capacity of plasma ribonucleases in leukemia].
Shliakhovenko VA; Negreĭ GZ; Glinskiĭ GV; Ivanova AB; Zyl' NI
Vopr Med Khim; 1982; 28(2):58-63. PubMed ID: 7080479
[TBL] [Abstract][Full Text] [Related]
35. [Studies on the heterogeneity of blood serum high-molecular fraction proteins in healthy people and patients with cancer].
Kostrzhevs'ka OG; Kolesnikova IM; Korotkoruchko VP; Grigor'eva TL
Ukr Biokhim Zh; 1977; 49(6):19-23. PubMed ID: 929705
[TBL] [Abstract][Full Text] [Related]
36. [Comparative characteristics of the leukocyte proteins in healthy persons and in patients with leukemia].
Voronchikhina LD; Tukachinskiĭ SE
Probl Gematol Pereliv Krovi; 1971 Mar; 16(3):14-8. PubMed ID: 5287008
[No Abstract] [Full Text] [Related]
37. [The prognostic role of complement activity in hemoblastoses].
Husieva SA; Klymenko LM; Dolia SM
Lik Sprava; 1993 Jul; (7):82-4. PubMed ID: 8209543
[TBL] [Abstract][Full Text] [Related]
38. [High molecular and euglobulin fractions of serum proteins in acute leukemia].
Mazurenko VA; Kostrzhevskaia EG; Dibrova TL; Korotkoruchko VP
Vrach Delo; 1983 Dec; (12):41-3. PubMed ID: 6670233
[No Abstract] [Full Text] [Related]
39. [Immunoelectrophoretic characterization of the changes in serum proteins in hemoblastosis].
Loginskiĭ VE
Vopr Med Khim; 1971; 17(4):384-8. PubMed ID: 5317620
[TBL] [Abstract][Full Text] [Related]
40. [The effect of the cationic proteins of human blood cells on the growth of Escherichia coli].
Rybakova LP; Zhdan-Pushkina SM
Zh Mikrobiol Epidemiol Immunobiol; 1990 May; (5):3-7. PubMed ID: 2201153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
